



NDA 21-572/S-048

**SUPPLEMENT APPROVAL**

Cubist Pharmaceuticals, LLC  
Attention: Karen R. Terry, RAC  
Manager, Global Regulatory Affairs  
65 Hayden Avenue  
Lexington, MA 02421

Dear Ms. Terry:

Please refer to your Supplemental New Drug Application (sNDA) dated December 3, 2014, received December 3, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cubicin (daptomycin for injection) Intravenous, 500 mg/vial.

We also acknowledge receipt of your amendments dated January 30 and March 27, 2015.

This "Prior Approval" supplemental new drug application provides for revisions to the carton and container labeling to facilitate packaging consistency across your product lines. Additionally, this supplement provides for editorial revisions to the **HIGHLIGHTS** section.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision listed below:

- Standard language relating to use of systemic antibacterial drug products (21 CFR 201.24) should be moved in **HIGHLIGHTS** from beneath the Initial US approval date to the end of the **INDICATIONS AND USAGE** section.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (which includes the above referenced revision), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels submitted on January 30, 2015, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 21-572/S-048.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

*{See appended electronic signature page}*

Sumathi Nambiar, MD, MPH  
Director  
Division of Anti-Infective Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SUMATHI NAMBIAR  
08/03/2015